What Parkinson’s disease is
Parkinson’s disease is a progressive neurological condition in which dopamine-producing cells in a region called the substantia nigra deteriorate. The main motor features are tremor, rigidity, slowness of movement, and postural instability. Non-motor symptoms such as pain, sleep disruption, anxiety, and cognitive decline are common and often become the greater source of disability as the condition advances. Standard treatment centres on levodopa and other dopaminergic medications, but these lose effectiveness over time and produce their own movement-related side effects.
Cannabis research on Parkinson’s disease
Four randomised controlled trials of cannabinoids for Parkinson’s disease have been published by mid-2026, and their results have been consistent: cannabinoid preparations have not outperformed placebo on primary endpoints.
A 2024 randomised trial of a high-CBD, low-THC cannabis extract in Parkinson’s disease reported no significant between-group difference on the motor MDS-UPDRS. Both groups improved, and several secondary measures including sleep, cognition, and activities of daily living numerically favoured the placebo arm.
A 2025 double-blind randomised controlled trial of sublingual CBD (mean 26 mg/day) in 60 Parkinson’s patients found the compound safe but produced no benefit on delayed recall — the primary cognitive outcome. The only statistically significant change was a small improvement in naming, a narrow cognitive subdomain.
A 2026 randomised controlled trial of a cannabis-based oral oil (43.88 mg CBD, 0.96 mg THC daily) for pain and other non-motor symptoms in Parkinson’s disease found the oil did not improve pain or any secondary non-motor measures relative to placebo after nine weeks.
Cognitive safety data from a 2023 Phase IIb randomised controlled trial of a high-dose CBD plus low-dose THC oral preparation showed that the active group performed worse on a verbal fluency test than placebo and reported cognitive adverse events at twice the rate.
Human observational evidence is limited but directionally different. A 2026 single-centre open-label prospective cohort study of self-titrated medical cannabis in 68 Parkinson’s patients reported statistically significant improvements on non-motor symptom scales for pain, sleep, and quality of life after three months. However, the dropout rate was 26.5% and there was no correlation between cannabinoid profile and clinical response. A 2023 retrospective chart review of 69 patients found that 87% had documented improvement in any Parkinson’s symptom after starting medical cannabis, with cramping, pain, spasticity, and tremor most frequently noted. Both studies are uncontrolled and subject to expectation bias.
Preclinical research has established that CB1 receptors are densely expressed in the basal ganglia, the brain region most affected by Parkinson’s disease. Animal models of Parkinson’s have shown that cannabinoid compounds can modulate dopamine signalling and reduce levodopa-induced dyskinesia. This biological rationale has not yet translated into efficacy in human randomised trials.
Compounds studied for Parkinson’s disease
THC is the cannabinoid most directly relevant to Parkinson’s disease research. Its activity at CB1 receptors in the basal ganglia provides a mechanistic basis for studying effects on tremor and dyskinesia, though the human randomised trials cited above have not demonstrated motor benefit from THC-containing preparations.
CBD has been the most-studied cannabinoid in Parkinson’s disease randomised trials. The published RCTs have consistently found CBD safe at the doses studied but have not shown benefit on motor, cognitive, or pain outcomes.
THCV has been of research interest because of its CB1 antagonist profile and presence in the basal ganglia. No human randomised trial in Parkinson’s disease has tested THCV in isolation at the time of writing.
Beta-caryophyllene is a dietary cannabinoid that activates CB2 receptors. In cell and animal models, CB2 activation has been associated with reduced neuroinflammation — a process relevant to Parkinson’s disease progression. Human clinical trial evidence linking beta-caryophyllene to Parkinson’s outcomes is absent.
Myrcene is a sedating terpene that has been studied in animal models for muscle-relaxant properties. No human clinical trial in Parkinson’s disease has isolated myrcene as a variable.
Limonene and linalool are terpenes with anxiolytic and mood-elevating properties in preclinical research. Anxiety and depression are common non-motor features of Parkinson’s disease, but no human studies have tested these terpenes as interventions for Parkinson’s-specific mood symptoms.
Limits of the evidence for Parkinson’s disease
Four randomised controlled trials now exist for cannabinoids in Parkinson’s disease. None has demonstrated superiority over placebo on a primary motor, pain, or cognitive endpoint. Two of these trials found signals of possible cognitive harm from THC-containing preparations.
The trial durations have been short: between two and sixteen weeks of treatment. Sample sizes have ranged from 58 to 68 participants. No randomised controlled trial has followed Parkinson’s patients on cannabinoids beyond a few months, so there are no controlled data on long-term safety or disease progression.
The human observational studies report improvement, but they are uncontrolled and subject to strong expectation effects. The 2024 randomised trial documented a marked placebo response on motor scores, which means open-label reports of benefit cannot be taken at face value.
No randomised controlled trial has tested whether cannabinoids reduce the need for dopaminergic medication over time. No trial has compared a cannabinoid preparation against an active comparator such as a dopamine agonist or a standard pain treatment. The animal data on dyskinesia and neuroprotection have not yet produced a positive human efficacy signal.
Sources
1. Liu Z, et al. Short-Term Cannabidiol with delta-9-Tetrahydrocannabinol in Parkinson’s Disease: A Randomized Trial. Movement Disorders. 2024. PMID: 38487964. Study record 2. Thongpang S, et al. Cannabidiol and cognitive functions/inflammatory markers in Parkinson’s disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial). BMC Neurology. 2025. PMID: 40267585. Study record 3. Peball M, et al. Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and delta9-Tetrahydrocannabinol Drug on Parkinson’s Disease-Related Motor Symptoms. Movement Disorders. 2023. PMID: 37212386. Study record 4. de Oliveira RW, et al. Cannabis-Based Oil for Pain and Other Non-Motor Symptoms in Parkinson’s Disease: A Randomized Controlled Trial. Movement Disorders Clinical Practice. 2026. PMID: 42563548. Study record 5. Barer Y, et al. Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson’s Disease. Movement Disorders Clinical Practice. 2026. PMID: 42304702. Study record 6. Yust-Katz S, et al. Medical Cannabis in the Treatment of Parkinson’s Disease. Clinical Neuropharmacology. 2023. PMID: 37191563. Study record
